Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, ISH etc. |
| Sample | cell lines (T24P, HT-1376 etc.) |
| Expression Pattern | up-regulated |
| Function Description | Nearly 100% of TCC patients highly expressed IGF2-P4 and H19, as determined by ISH and by qPCR. The double promoter vector exhibited superior tumor growth inhibition activity compared to the single promoter expression vectors, in cell lines and in heterotopic and orthotopic bladder tumors. Bladder tumors may be successfully treated by intravesical instillation of the double promoter vector H19-DTA-P4-DTA. Overall, the double promoter vector exhibited enhanced anti-cancer activity relative to single promoter expression vectors carrying either gene alone. |
| Pubmed ID | 21162716 |
| Year | 2010 |
| Title | Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |